Dr. Robert Spiegel is an independent director at Geron, a late-stage clinical biopharmaceutical company. He has served on the company’s board since 2010.
Dr. Spiegel serves on various other boards, including Athenex, Sun Pharma, Ayala Pharmaceuticals, and Cyclacel Pharmaceuticals. He is a professor at Weill Cornell Medicine and a fellow at the University of Pennsylvania’s Center for Bioethics.
In addition to board service, Dr. Spiegel engages in private equity consulting, as CEO of his firm, Spiegel Consulting. He also serves as a senior advisor to private equity firm, Warburg Pincus, and to the venture investment fund, Israel Biotech. Over the years, he has gained meaningful R&D, clinical, and operational experience in the biopharmaceutical industry—including biotech, big pharma, and academic startups.
Dr. Spiegel was previously the chief medical officer for PTC Therapeutics, as well as a director for both Cancer Care New Jersey and the Cancer Institute of New Jersey.
Other significant experience includes 26 years at Schering-Plough (now Merck & Co.). He joined the company as its director of clinical research in oncology, and later advanced to other senior positions in clinical research. His last role at Schering-Plough was chief medical officer, where he presided over at least 30 drug applications for FDA approval, participated in due diligence surveys, re-engineered pharmacovigilance and risk management, and established a quality framework for research operations, among other responsibilities.
Early on in his career, following an internal medicine residency, Dr. Spiegel took a medical oncology fellowship with the National Cancer Institute, and he ended up holding academic positions both there and at the New York University Cancer Center for nearly 20 years.
Dr. Spiegel earned his B.A. at Yale University and his M.D. at the University of Pennsylvania. He went through his specialty training at the NCI, NIH.
What is Robert J. Spiegel's net worth?
The estimated net worth of Robert J. Spiegel is at least $155,912.16 as of September 13th, 2018. Dr. Spiegel owns 110,576 shares of Geron stock worth more than $155,912 as of May 1st. This net worth estimate does not reflect any other investments that Dr. Spiegel may own. Learn More about Robert J. Spiegel's net worth.
How do I contact Robert J. Spiegel?
The corporate mailing address for Dr. Spiegel and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at investor@geron.com. Learn More on Robert J. Spiegel's contact information.
Has Robert J. Spiegel been buying or selling shares of Geron?
Robert J. Spiegel has not been actively trading shares of Geron during the last quarter. Most recently, Robert J. Spiegel sold 175,000 shares of the business's stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.85, for a transaction totalling $1,198,750.00. Following the completion of the sale, the director now directly owns 110,576 shares of the company's stock, valued at $757,445.60. Learn More on Robert J. Spiegel's trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 7.4% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
